Companies › Eirion Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AI-09 Ready Use Injectable Botulinum Toxin Botulinum toxin type A - cleaves SNARE proteins, blocking acetylcholine release at the neu | SNARE | Phase 2 | Glabellar Lines | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07321834 | AI-09 Ready Use Injectable Botulinum Toxin | Phase 2 | Glabellar Lines | Other | Feb 2026 |
Ascendis Pharma Endocrinology Division Airway Therapeutics Inotrem Ascendis Pharma Growth Disorders Tego Science
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.